

This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### *LIN*-BENZOARISTEROMYCIN

Vasanthakumar P. Rajappan<sup>a</sup>; Stewart W. Schneller<sup>a</sup>

<sup>a</sup> Department of Chemistry, Auburn University, Auburn, Alabama, U.S.A.

Online publication date: 31 March 2001

**To cite this Article** Rajappan, Vasanthakumar P. and Schneller, Stewart W.(2001) '*LIN*-BENZOARISTEROMYCIN', Nucleosides, Nucleotides and Nucleic Acids, 20: 4, 1117 — 1121

**To link to this Article:** DOI: 10.1081/NCN-100002501

**URL:** <http://dx.doi.org/10.1081/NCN-100002501>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## LIN-BENZOARISTEROMYCIN

Vasanthakumar P. Rajappan and Stewart W. Schneller\*

Department of Chemistry, Auburn University, Auburn, Alabama 36849

### ABSTRACT

A synthesis and an antiviral analysis of the *linear* extended derivative of aristeromycin (**2**) is described.


It has been 25 years since Leonard and co-workers introduced the concept of spatially separating the pyrimidino and imidazo units of the purine ring with 4  $sp^2$  carbon atoms (**1**). These derivatives were referred to as benzo-separated purines (as in adenine, **1**). Numerous variations, including nucleoside derivatives, based on the Leonard concept have arisen and have found biological applications (**2**). In view of extensive interest in carbocyclic nucleosides (**3**) and our particular focus on the antiviral properties of aristeromycin (**2**) (**4**), we sought *lin*-benzoaristeromycin (**3**) (**5**). The results of that study are reported herein.

The synthesis of **3** began by generating the anion of 8-methylthioimidazo[4,5-*g*]-quinazoline (**4**) (**1**) and reacting it with triflate **5** (**6**) to give a single regioisomer, **6** (**7**) (Scheme). The structure of **6** was proven by comparing its  $^1H$  and  $^{13}C$  NMR chemical shift values in the aromatic moiety with the *lin*-benzo-5'-noraristeromycin precursor (**7**), whose structure has been unambiguously assigned by us (**8**). Subjecting **6** to refluxing in methanol saturated with ammonia gave **8**. Hydrolysis of **8** using 2:1 trifluoroacetic acid-water mixture provided **3**. The overall yield of **3** from **4** and **5** was 12%.


Compound **3** was evaluated for its effectiveness towards the following viruses: parainfluenza-3, respiratory syncytial, vesicular stomatitis, sindbis, punta toro, coxsackie B4, reo, herpes simplex 1 ( $TK^+$  and  $TK^-$ ), herpes simplex 2, and vaccinia.

---


\*Corresponding author.



Scheme<sup>a</sup>



<sup>a</sup>Reaction conditions: *a*, NaH, 18-C-6, DMF, room temp.; *b*, NH<sub>3</sub>/MeOH, 120°C; *c*, CF<sub>3</sub>CO<sub>2</sub>H/H<sub>2</sub>O, 50°C.



No activity was found. This observation suggests that extending the ring system of aristeromycin in the linear way represented by **3** prevented its association with the enzymes (kinases and *S*-adenosyl-L-homocysteine hydrolase) (9) responsible for its antiviral characteristics.

## EXPERIMENTAL

Melting points were recorded on a Meltemp II melting point apparatus and are uncorrected. The combustion analysis was performed at Atlantic Microlab, Norcross, GA.  $^1\text{H}$  and  $^{13}\text{C}$  spectra were recorded on a Bruker AC 250 spectrometer (operated at 250 and 62.5 MHz, respectively) all referenced to internal tetramethylsilane (TMS) at 0.0 ppm. The spin multiplicities are indicated by the symbols s (singlet), d (doublet), dd (doublet of doublets), ddd (doublet of doublets of doublets), m (multiplet) and br (broad). The optical rotation was measured on a JASCO DIP-360 polarimeter. Reactions were monitored by thin-layer chromatography (TLC) using 0.25 mm Whatman Diamond silica gel 60-F<sub>254</sub> precoated plates with visualization by irradiation with a Mineralight UVGL-25 lamp. Column chromatography was performed on Whatman silica, 230–400 mesh, 60 Å and elution with the indicated solvent system. Yields refer to chromatographically and spectroscopically ( $^1\text{H}$  and  $^{13}\text{C}$  NMR) homogeneous materials.

**8-Amino-3-[(1'*R*,2'*S*,3'*R*,4'*R*)-2',3'-dihydroxy-4'-hydroxymethyl]cyclopent-1'-yl]imidazo[4,5-*g*]quinazoline (**3**).** To a suspension of **4** (**1**) (1.5 g, 7 mmol), NaH (175 mg, 7 mmol) and 18-crown-6 (1.85 g, 7 mmol) in anhydrous DMF (50 mL) heated at 70°C for 1 hour and then cooled to 0°C was added a solution of **5** (**6**) (1.79 g, 5.25 mmol) in anhydrous DMF (15 mL). The mixture was stirred at 0°C for 9 hours and then at room temperature for 24 hours. The mixture was filtered, the filtrate evaporated and the residue adsorbed onto silica gel and this was loaded onto a silica gel column. Impurities were eluted with  $\text{CH}_2\text{Cl}_2$ -MeOH (60:1) followed by elution of the product fractions with  $\text{CH}_2\text{Cl}_2$ -MeOH (40:1 mL). After evaporation of the solvent, the residue was triturated with ether and filtered. The filtrate on evaporation gave 950 mg (40%) of 3-[(1'*R*,2'*S*,3'*R*,4'*R*)-4'-*tert*-butoxymethyl-2',3'-isopropylidenedioxycyclopent-1'-yl]-8-methylthioimidazo-[4,5-*g*]quinazoline (**6**) as a light yellow gummy residue;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.97 (s, 1H), 8.48 (s, 1H), 8.40 (s, 1H), 8.33 (s, 1H), 5.30 (m, 1H), 4.65 (m, 3H), 3.57 (m, 2H), 2.65 (s, 3H), 2.56 (m, 1H), 1.75 (s, 3H), 1.43 (s, 3H), 1.38 (m, 1H), 1.23 (s, 9H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  158.94, 138.67, 137.45, 133.97, 131.76, 123.12, 107.84, 105.34, 101.01, 92.03, 72.80, 68.80, 60.36, 57.74, 49.95, 48.83, 31.19, 19.56, 15.58, 14.82, 12.52.

To a saturated solution of ammonia in anhydrous methanol (70 mL) was added a solution of **6** (500 mg, 1.13 mmol) in methanol (50 mL). The mixture was heated in a pressure reactor at 120°C (oil bath) for 36 hours. After cooling the mixture was filtered, the filtrate evaporated and the residue placed on a silica gel column. The product was eluted using  $\text{CH}_2\text{Cl}_2$ -MeOH (15:1). After evaporation of the



solvent, the residue was triturated with ether to give 280 mg (60%) of 8-amino-3-[(1'*R*,2'*S*,3'*R*,4'*R*)-4'-*tert*-butoxymethyl-2',3'-isopropylidenedioxycyclopent-1'-yl]-imidazo[4,5-*g*]quinazoline (**8**) as a light yellow powder, which was used in the next reaction without further purification, mp 154–156°C; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 8.54 (s, 1H), 8.53 (s, 1H), 8.38 (s, 1H), 7.94 (s, 1H), 7.87 (br s, 2H), 5.15 (dd, *J* = 5, 7.5 Hz, 1H), 4.85 (m, 1H), 4.60 (m, 1H), 3.48 (d, *J* = 7.5 Hz, 2H), 3.39 (m, 1H), 2.46 (m, 1H), 2.05 (m, 1H), 1.54 (s, 3H), 1.28 (s, 3H), 1.14 (s, 9H).

A solution of **8** (140 mg, 0.34 mmol) in CF<sub>3</sub>CO<sub>2</sub>H-H<sub>2</sub>O (15 mL, 2:1) was heated at 50°C for 3 hours. After evaporation of the solvent, the residue was adsorbed onto silica gel (1 g) and this was loaded onto a silica gel column. The product was eluted using CH<sub>2</sub>Cl<sub>2</sub>-MeOH (4:1). Evaporation of the solvent and trituration of the residue with ether gave **3** as an off white powder (80 mg, 75%), mp >280°C (charred) [ $\alpha$ ]<sub>D</sub><sup>24</sup> -17.90 (c 0.41 in Me<sub>2</sub>SO); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>): δ 8.70 (s, 1H), 8.56 (s, 1H), 8.37 (s, 1H), 7.93 (s, 1H), 7.89 (br s, 2H), 5.11 (m, 2H), 4.83 (dd, *J* = 7.5, 10 Hz, 1H), 4.42 (ddd, *J* = 5, 5, 5 Hz, 1H), 3.89 (d, *J* = 2.5 Hz, 1H), 3.52 (m, 3H), 2.48 (m, 1H), 2.13 (m, 1H), 1.59 (m, 1H); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>) δ 162.21, 152.87, 147.84, 147.53, 143.76, 133.92, 114.57, 108.23, 104.13, 74.77, 71.70, 62.98, 59.90, 45.38, 29.32. *Anal.* Calcd. for C<sub>15</sub>H<sub>17</sub>N<sub>5</sub>O<sub>3</sub>·0.60 H<sub>2</sub>O: C 55.24; H 5.62; N 21.47. Found: C 55.39; H 5.45; N 21.16.

### ACKNOWLEDGMENTS

This research was supported by funds from the Department of Health and Human Services (AI31718 and AI48495), which is appreciated. We are indebted to Dr. E. De Clercq, Rega Institute, Leuven, Belgium for providing the antiviral assays.

### REFERENCES

1. Leonard, N.J.; Morrice, A.G.; Sprecker, M.A. *J. Org. Chem.* **1975**, *40*, 356–363.
2. For example, (a) Leonard, N.J.; Hiremath, S.P. *Tetrahedron* **1986**, *42*, 1917–1986. (b) Devadas, B.; Leonard, N.J. *J. Am. Chem. Soc.* **1990**, *112*, 3125–3135. (c) Leonard, N.J.; Bhat, B.; Wilson, S.R.; Cruickshank, K.A. *J. Am. Chem. Soc.* **1991**, *113*, 1398–1406. (d) Dempcy, R.O.; Skibo, E.B. *J. Org. Chem.* **1991**, *56*, 776–785. (e) Hijazi, A.; Pfeiderer, W. *Nucleosides Nucleotides* **1984**, *3*, 549–557. (f) Chung, F.-L.; Schram, K.H.; Panzica, R.P.; Earl, R.A.; Wotring, L.L.; Townsend, L.B. *J. Med. Chem.* **1980**, *23*, 1158–1166.
3. Crimmins, M.T. *Tetrahedron* **1998**, *54*, 9229–9272.
4. For a leading reference, see Seley, K.L.; Schneller, S.W.; Korba, B. *Nucleosides Nucleotides* **1997**, *16*, 2095–2099.
5. Unsuccessful preliminary approaches to **3** have been described (Leahy, J.W.; Schneller, S.W. 200<sup>th</sup> ACS National Meeting, Division of Medicinal Chemistry, Abstract 144, 1990).



**LIN-BENZOARISTEROMYCIN**

**1121**

6. Wang, P.; Agrofoglio, L.A.; Newton, M.G.; Chu, C.K. *J. Org. Chem.* **1999**, *64*, 4173–4178.
7. Zhang, J.; Nair, V. *Nucleoside Nucleotides* **1997**, *16*, 1091–1094 reported both products when alkylating **5** with a 1',3'-dideoxy-2'-ribofuranosyl tosylate.
8. Rajappan, V.; Schneller, S.W. *J. Org. Chem.* submitted.
9. Wolfe, M.S.; Borchardt, R.T. *J. Med. Chem.* **1991**, *34*, 1521–1530.



## **Request Permission or Order Reprints Instantly!**

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

**[Order now!](#)**

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002501>